Leuko
Our device, PointCheck™, shines light into the skin near the fingernail, images blood flow in superficial capillaries, and assesses whether white blood cell levels are dangerously low. That drop, severe neutropenia, leaves people on chemotherapy open to life-threatening infection, and today it can only be caught with a blood test.
Leuko spun out of MIT and the Madrid-MIT M+Visión Consortium, and is based in Cambridge, Massachusetts and Madrid. It is backed by venture investors and NIH/NCI grants, and works with leading cancer centres in the US and Europe.
As CTO I lead the technology: taking a new optical measurement from the lab bench to a device used at home in clinical trials, across optics, hardware, electronics, and embedded and cloud software. I co-invented the core patented technology behind it.
- $15M venture and grant funding
- 8 top cancer centres collaborating
- 1 pivotal clinical trial underway
leuko.com
MIT News, 2024
$4.5M NIH grant, 2024